# Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Study · id `cardio:ct-nct02929329` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02929329](<https://clinicaltrials.gov/study/NCT02929329>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02929329

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8256 participants.

## Technical summary

Registry record NCT02929329. Randomized; triple masking; primary purpose treatment. Start 2017-01-06 (actual); primary completion 2020-09-14 (actual). Results posted on 2021-07-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 8256 participants (enrolled count; ClinicalTrials.gov record NCT02929329, source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)
- Started: 2017-01-06 (actual) (ClinicalTrials.gov record NCT02929329, source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)
- Primary completion: 2020-09-14 (actual) (ClinicalTrials.gov record NCT02929329, source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)
- Completion: 2020-09-14 (actual) (ClinicalTrials.gov record NCT02929329, source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)
- Results first posted: 2021-07-20 (ClinicalTrials.gov record NCT02929329, source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hungary; Italy; Japan; Lithuania; Mexico; Netherlands; New Zealand; Poland; Portugal; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Sweden; Switzerland; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02929329, source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02929329-2021-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
- Acronym: GALACTIC-HF
- Condition: Heart Failure
- Intervention (Drug): Omecamtiv Mecarbil
- Intervention (Drug): Placebo
- Intervention (Drug): Standard of Care
- Lead sponsor: Cytokinetics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Cytokinetics (`cardio:org-cytokinetics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure (`cardio:pubmed-33185990`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial (`cardio:pubmed-34643642`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial (`cardio:pubmed-35325102`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial (`cardio:pubmed-36597719`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial (`cardio:pubmed-37831045`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study (`cardio:pubmed-38215932`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial (`cardio:pubmed-41123512`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF (`cardio:pubmed-41528277`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF (`cardio:pubmed-41771088`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1f3567d36fed402a428692fde6c9e192428591ddf37e8e1c011398c7e28755e6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
